Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

4.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.7K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

11.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.0K
Introduction to Fibroblasts01:09

Introduction to Fibroblasts

4.2K
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
4.2K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

3.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

615
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
615
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

10.8K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lysosomes and lysosomal dysfunction in ageing biology.

Nature cell biology·2026
Same author

SON-dependent nuclear speckle rehabilitation alleviates proteinopathies.

Nature communications·2025
Same author

NSP7 Molecular Degrader Attenuates Coronaviral Infection Through the β-TrCP1/FBXO5 Axis.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Inhibition of virally induced TFEB proteasomal degradation as a host-centric therapeutic approach for coronaviral infection.

Science advances·2025
Same author

A small-molecule inhibitor of BCL10-MALT1 interaction abrogates progression of diffuse large B cell lymphoma.

The Journal of clinical investigation·2025
Same author

Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients.

PloS one·2024

Related Experiment Video

Updated: Mar 14, 2026

Ex Vivo Corneal Organ Culture Model for Wound Healing Studies
06:46

Ex Vivo Corneal Organ Culture Model for Wound Healing Studies

Published on: February 15, 2019

12.6K

Therapeutic targets in fibrotic pathways.

Travis Lear1, Bill B Chen2

  • 1Department of Environmental and Occupational Health, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA; Department of Medicine, Acute Lung Injury Center of Excellence, University of Pittsburgh, Pittsburgh, PA 15213, USA.

Cytokine
|September 23, 2016
PubMed
Summary

Researchers identified Fibrosis Inducing E3 Ligase 1 (FIEL1) as a key regulator in pulmonary fibrosis. Inhibiting FIEL1 shows promise for treating this complex lung disease.

Keywords:
FIEL1FibrosisIPFTGFbetaUbiquitin

More Related Videos

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.7K
Author Spotlight: Understanding Chronic Lung Diseases Using 3D Printed Phototunable Hydrogels
07:17

Author Spotlight: Understanding Chronic Lung Diseases Using 3D Printed Phototunable Hydrogels

Published on: June 30, 2023

2.4K

Related Experiment Videos

Last Updated: Mar 14, 2026

Ex Vivo Corneal Organ Culture Model for Wound Healing Studies
06:46

Ex Vivo Corneal Organ Culture Model for Wound Healing Studies

Published on: February 15, 2019

12.6K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.7K
Author Spotlight: Understanding Chronic Lung Diseases Using 3D Printed Phototunable Hydrogels
07:17

Author Spotlight: Understanding Chronic Lung Diseases Using 3D Printed Phototunable Hydrogels

Published on: June 30, 2023

2.4K

Area of Science:

  • Pulmonary Medicine
  • Molecular Biology
  • Drug Discovery

Background:

  • Pulmonary fibrosis is a complex lung disease with heterogeneous pathogenesis, presenting therapeutic challenges.
  • Transforming growth factor-beta (TGF-β) signaling is a critical pathway implicated in driving fibrotic processes and reducing lung function.

Purpose of the Study:

  • To investigate the role of the E3 ligase Fibrosis Inducing E3 Ligase 1 (FIEL1) in regulating TGF-β signaling and pulmonary fibrosis.
  • To evaluate the therapeutic potential of targeting FIEL1 in preclinical models of lung fibrosis.

Main Methods:

  • Investigated the interaction between FIEL1 and PIAS4 in the context of TGF-β signaling.
  • Utilized bleomycin-induced murine models to assess the impact of FIEL1 modulation on pulmonary fibrosis.
  • Developed and tested a small molecule inhibitor of FIEL1 (BC-1485).

Main Results:

  • FIEL1 was identified as a regulator of TGF-β signaling via selective degradation of PIAS4.
  • FIEL1 exacerbates bleomycin-induced pulmonary fibrosis in mice; FIEL1 silencing attenuates this fibrotic phenotype.
  • The FIEL1 inhibitor BC-1485 prevented PIAS4 degradation and ameliorated fibrosis in murine models.

Conclusions:

  • FIEL1 is a significant regulator in the pathogenesis of pulmonary fibrosis.
  • Targeting the FIEL1/PIAS4 pathway represents a promising therapeutic strategy for pulmonary fibrosis.